Anti-VEGF therapy may revolutionize ROP treatment

A single intravitreal injection of an anti-VEGF agent in babies with retinopathy of prematurity

induces regression of pathological neovascularization and also promotes resumption of

physiological vascularization of the retina, Tim U Krohne MD of the University of Bonn Eye

Clinic told the World Society of Paediatric Ophthalmology & Strabismus. As such, it could

eliminate the need to ablate avascular retina tissue and has the potential to revolutionize ROP

treatment.

However, several issues must be addressed before anti-VEGF is adopted, Dr Krohne said. These

include establishing the smallest effective dose and assessing safety with particular attention to

systemic side effects. Injection sight is also an issue since premature infant eyes are very small.

Managing aberrations after laser refractive surgery requires a multi-layered approach.

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.

From monofocal to full-range solutions, each practice needs comprehensive understanding.

A world-first trial suggests a new medication could beat the disease.

Femtosecond lasers are helping improve refractive results with fewer problems.

Lens power adjustment technology is developing quickly.